Dermata Therapeutics, Inc. (DRMAW) 股票分析

公司概述

Dermata Therapeutics, Inc. is a late-stage medical dermatology company dedicated to the identification, development, and commercialization of pharmaceutical product candidates designed for the treatment of medical skin diseases as well as aesthetic applications. Although the specific sector and industry classifications are not explicitly defined in the available data, the company's operational focus is clearly concentrated within the specialized pharmaceutical and dermatological therapeutic space. The firm currently employs a small workforce of nine individuals, indicating a lean organizational structure typical of entities in the late-stage development phase. Given that the market capitalization, annual revenue, and specific industry classification are not disclosed in the provided facts, the company's overall market position cannot be quantified by traditional capitalization metrics, suggesting it operates with a niche focus rather than broad market dominance.

财务健康

The company reported a net income of $-7,558,557 for the trailing twelve months, while revenue and EBITDA figures are not available in the current dataset. The substantial gap between the reported net income loss and the zero revenue implies that the company is incurring significant operating costs and research expenses that exceed its current revenue generation, a pattern characteristic of pre-commercialization biotech firms. Free cash flow stands at $-5,016,645, indicating that the company is consuming cash to fund its development activities rather than generating surplus liquidity from operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the fact that the company has not yet achieved profitability or scaled revenue to cover costs. The balance sheet is supported by $7.52M in cash and $0 in debt, creating a conservative financial profile with no leverage. With a current ratio of 4.79, the company maintains robust short-term liquidity, ensuring it can meet its obligations despite the ongoing cash burn. Return on Equity is -194.2% and Return on Assets is -85.3%, metrics that reveal the company is currently utilizing shareholder capital and assets to generate losses rather than returns, a common status for entities in the high-risk, high-reward late-stage clinical development phase.

估值评估

Trailing P/E, forward P/E, price-to-sales ratio, and EV/EBITDA are all listed as N/A, indicating that traditional earnings-based valuation multiples are not applicable to the company at this stage of development. The price-to-book ratio is 0.01, which suggests that the market values the company at a fraction of its book value, often seen in capital-intensive or loss-making biotechnology firms where assets are undervalued on the balance sheet relative to future potential. The 52-week high is $0.02 and the 52-week low is $0.01, placing the stock's trading range within a very narrow band typical of micro-cap or penny stocks. The beta of 0.50 indicates that the stock's price volatility is significantly lower than the broader market, suggesting a defensive or low-correlation behavior relative to general market movements. Without traditional valuation multiples, investors must rely on alternative metrics such as the price-to-book ratio and the depth of the company's cash reserves to assess value.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are not available in the provided data, precluding an analysis of the trajectory between revenue expansion and earnings improvement. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by the absence of a dividend yield and payout ratio. Instead of paying dividends, the company directs all available cash flow toward funding its Phase 3 clinical trials and commercialization efforts for its lead product candidate, XYNGARI. The overall growth and income profile is defined by a lack of current profitability and dividend income, with the primary value proposition derived from the potential success of its late-stage product candidates rather than current operational cash flows or income generation.